09.08.2016 Views

Hepatitis C Drug Market

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

Published By: Zion Research<br />

<strong>Hepatitis</strong> C <strong>Drug</strong> <strong>Market</strong> for (Hospitals, Private Labs, Physician<br />

Offices, Public Health Labs and Blood Banks) by Application -<br />

Global Industry Perspective, Comprehensive Analysis, Size,<br />

Share, Growth, Segment, Trends and Forecast, 2015 – 2021<br />

Joel John<br />

3422 SW 15 Street, Suit #8138,<br />

Deerfield Beach,<br />

Florida 33442, USA<br />

Tel: +1-386-310-3803<br />

Toll Free: 1-855-465-4651<br />

www.marketresearchstore.com<br />

sales@marketresearchstore.com


<strong>Hepatitis</strong> C <strong>Drug</strong> <strong>Market</strong><br />

Zion Research has published a new report titled “<strong>Hepatitis</strong> C <strong>Drug</strong> <strong>Market</strong> for (Hospitals,<br />

Private Labs, Physician Offices, Public Health Labs and Blood Banks) by Application - Global<br />

Industry Perspective, Comprehensive Analysis and Forecast, 2015 – 2021” According to the<br />

report, global demand for hepatitis C drug market was valued at USD 11.81 billion in<br />

2015, is expected to reach USD 27.63 billion in 2021 and is anticipated to grow at a<br />

CAGR of 17% between 2016 and 2021.<br />

Request Report Sample http://www.marketresearchstore.com/report/hepatitis-cdrug-market-z62423<br />

HCV is a major public health problem that attacks the liver and leads to inflammation. Certain<br />

drugs, toxins, heavy alcohol use, bacterial and viral infections can cause hepatitis infection. The<br />

most common types of hepatitis infections are <strong>Hepatitis</strong> A, <strong>Hepatitis</strong> B, and <strong>Hepatitis</strong> C and they<br />

are caused by three dissimilar dissimilar viruses. Although each virus can cause similar<br />

symptoms, they have different modes of transmission and can affect the liver differently.<br />

sales@marketresearchstore.com


<strong>Hepatitis</strong> C <strong>Drug</strong> <strong>Market</strong><br />

<strong>Hepatitis</strong> C infection can bring both acute and chronic hepatitis disease. Approximately, 80% of<br />

patients get chronically infected with hepatitis C disease. <strong>Hepatitis</strong> C infection (HCV) spreads<br />

through the blood of infected individual by the use of shared needles or supplies used to infuse<br />

drugs. Vaccines are available only for <strong>Hepatitis</strong> A and <strong>Hepatitis</strong> B viruses. Research into the<br />

development of a vaccine for hepatitis C is under way.<br />

<strong>Hepatitis</strong> C <strong>Drug</strong> <strong>Market</strong>: Inquiry<br />

for buying report http://www.marketresearchstore.com/report/hepatitis-c-drugmarket-z62423#InquiryForBuying<br />

The prevalence of the infection, new productive treatments, relatively lesser time of treatment<br />

from before, and rising government subsidizing, can drive the hepatitis C drug market. Lack of<br />

awareness and information about HCV and treatment expense of disease can influence the<br />

hepatitis C market. In the last few years a couple of new drugs have been launched in the market<br />

which has huge success and captured maximum market share of the hepatitis C market.<br />

However, cost of these drugs is too high. Hospitals, private labs, physician offices, public health<br />

labs, and blood banks are the key application of hepatitis C drug market.<br />

sales@marketresearchstore.com


<strong>Hepatitis</strong> C <strong>Drug</strong> <strong>Market</strong><br />

North America was one of the fastest growing hepatitis C drug markets across the world with<br />

more than 40% share of the total revenue generated in 2015. U. S. is the largest revenue<br />

contributor for worldwide <strong>Hepatitis</strong> C market. Government funding for drug development will<br />

continue to play an essential role in the growth of U.S. HCV treatment market. Europe was the<br />

second major market for <strong>Hepatitis</strong> C in 2015.<br />

Ongoing research and development in pharmaceutical industry for hepatitis C drug<br />

development is expected to propel the market growth in the coming years. Moreover, interest for<br />

<strong>Hepatitis</strong> C medication is expanding in Asia Pacific, Latin America and Middle East and Africa<br />

due to prevalence of the disease in the regions combined with expenditure on healthcare<br />

infrastructure.<br />

<strong>Hepatitis</strong> C <strong>Drug</strong> <strong>Market</strong>: Browse the full report<br />

at http://www.marketresearchstore.com/report/hepatitis-c-drug-market-z62423<br />

Harvoni and Sovaldi are newly discovered drugs for <strong>Hepatitis</strong> C. <strong>Market</strong>ed by pharmaceutical<br />

giant Gilead Sciences and has more than 95% cure rate. The problem with this drug is its high<br />

sales@marketresearchstore.com


<strong>Hepatitis</strong> C <strong>Drug</strong> <strong>Market</strong><br />

cost, Harvoni drug is one of the expensive drug in the world. Some of the key player in the<br />

hepatitis C drug market includes Merck & Co, Kenilworth, Roche, Basel GlaxoSmith, Gilead<br />

Sciences, AbbVie, Johnson & Johnson and Bristol-Myers Squibb.<br />

The report segments the global hepatitis C drug market as<br />

<strong>Hepatitis</strong> C <strong>Drug</strong> <strong>Market</strong>: Table of<br />

Content http://www.marketresearchstore.com/report/hepatitis-c-drug-marketz62423#tableOfContent<br />

<strong>Hepatitis</strong> C <strong>Drug</strong> <strong>Market</strong>: Application Segment Analysis<br />

<br />

<br />

<br />

Hospitals<br />

Private labs<br />

Physician offices<br />

sales@marketresearchstore.com


<strong>Hepatitis</strong> C <strong>Drug</strong> <strong>Market</strong><br />

<br />

<br />

Public health labs<br />

Blood banks<br />

<strong>Hepatitis</strong> C <strong>Drug</strong> <strong>Market</strong>: Regional Segment Analysis<br />

<br />

<br />

<br />

<br />

North America<br />

o U.S.<br />

Europe<br />

o Germany<br />

o UK<br />

o France<br />

Asia Pacific<br />

o China<br />

o Japan<br />

o India<br />

Latin America<br />

o Brazil<br />

sales@marketresearchstore.com


<strong>Hepatitis</strong> C <strong>Drug</strong> <strong>Market</strong><br />

<br />

Middle East and Africa<br />

<br />

<br />

<br />

Chapter 1. Preface<br />

o 1.1. Report description and scope<br />

o 1.2. Research scope<br />

o 1.3. Research methodology<br />

• 1.3.1. <strong>Market</strong> research process<br />

• 1.3.2. <strong>Market</strong> research methodology<br />

Chapter 2. Executive Summary<br />

o 2.1. Global hepatitis C drug market, 2015 - 2021, (USD Billion)<br />

o 2.2. <strong>Hepatitis</strong> C drug: market snapshot<br />

Chapter 3. <strong>Hepatitis</strong> C <strong>Drug</strong> <strong>Market</strong>: Industry Analysis<br />

o<br />

o<br />

o<br />

3.1. <strong>Hepatitis</strong> C drug : <strong>Market</strong> dynamics<br />

3.2. <strong>Market</strong> Drivers<br />

• 3.2.1. Increasing incidences of the disease<br />

• 3.2.2. New efficient therapies and comparatively smaller period of treatment<br />

• 3.2.3. Rising government funding<br />

3.3. Restraints<br />

sales@marketresearchstore.com


<strong>Hepatitis</strong> C <strong>Drug</strong> <strong>Market</strong><br />

<br />

• 3.3.1. Lack of awareness and information about HCV<br />

• 3.3.2. Treatment cost<br />

• 3.3.3. Threat related with regulation and development of drug<br />

o 3.4. Opportunity<br />

• 3.4.1. Advancing technologies and ongoing research<br />

o 3.5. Porter’s Five Forces Analysis<br />

o 3.6. <strong>Market</strong> Attractiveness Analysis<br />

• 3.6.1. <strong>Market</strong> attractiveness analysis by application segment<br />

• 3.6.2. <strong>Market</strong> attractiveness analysis by regional segment<br />

Chapter 4. Global hepatitis C drug market: Competitive Landscape<br />

<strong>Hepatitis</strong> C <strong>Drug</strong> <strong>Market</strong>: Browse the full report<br />

at http://www.marketresearchstore.com/report/hepatitis-c-drug-market-z62423<br />

o<br />

o<br />

4.1. Company <strong>Market</strong> Share Analysis<br />

• 4.1.1. Global hepatitis C drug market: company market share, 2015<br />

4.2. Strategic Development<br />

• 4.2.1. Acquisitions & Mergers<br />

• 4.2.2. New Product Launch<br />

• 4.2.3. Agreements, Partnerships, Collaborations and Joint Ventures<br />

• 4.2.4. Research and Development, Product and Regional Expansion<br />

sales@marketresearchstore.com


<strong>Hepatitis</strong> C <strong>Drug</strong> <strong>Market</strong><br />

<br />

<br />

o<br />

o<br />

4.3. Price Trend Analysis<br />

4.4. Product Portfolio<br />

o 4.5. Patent Analysis (2011-2016)<br />

• 4.5.1. Patent Trend<br />

• 4.5.2. Patent Share by company<br />

• 4.5.3. By Region<br />

Chapter 5. Global hepatitis C market: Application Overview<br />

o 5.1. Global hepatitis C drug market share, by application, 2015 and 2021<br />

o 5.2. Global hepatitis C drug market for hospitals, 2015 - 2021(USD Billion)<br />

o 5.3. Global hepatitis C drug market for private labs , 2015 - 2021 (USD Billion)<br />

o 5.4. Global hepatitis C drug market for physician offices, 2015 - 2021 (USD Billion)<br />

o 5.5. Global hepatitis C drug market for public health labs, 2015 - 2021 (USD Billion)<br />

o 5.6. Global hepatitis C drug market for blood banks, 2015 - 2021 (USD Billion)<br />

Chapter 6. Global hepatitis C drug market: Regional Analysis<br />

o<br />

o<br />

6.1. Global hepatitis C drug market: Regional overview<br />

• 6.1.1. Global hepatitis C drug market share, by region, 2015 and 2021<br />

6.2. North America<br />

• 6.2.1. North America hepatitis C drug market revenue, by application, 2015 –<br />

2021 (USD Billion)<br />

• 6.2.2. U.S.<br />

• 6.2.3. U.S. hepatitis C drug market revenue, by application, 2015 – 2021 (USD<br />

Billion)<br />

sales@marketresearchstore.com


<strong>Hepatitis</strong> C <strong>Drug</strong> <strong>Market</strong><br />

o<br />

6.3. Europe<br />

• 6.3.1. Europe hepatitis C drug market revenue, by application, 2015 – 2021 (USD<br />

Billion)<br />

• 6.3.2. UK<br />

• 6.3.2.1. UK hepatitis C drug market revenue, by application, 2015 – 2021<br />

(USD Billion)<br />

• 6.3.3. France<br />

• 6.3.3.1. France hepatitis C drug market revenue, by application, 2015 –<br />

2021 (USD Billion)<br />

• 6.3.4. Germany<br />

• 6.3.4.1. Germany hepatitis C drug market revenue, by application, 2015 –<br />

2021 (USD Billion)<br />

<strong>Hepatitis</strong> C <strong>Drug</strong> <strong>Market</strong>: Browse the full report<br />

at http://www.marketresearchstore.com/report/hepatitis-c-drug-market-z62423<br />

o<br />

6.4. Asia Pacific<br />

• 6.4.1. Asia-Pacific hepatitis C drug market revenue, by application, 2015 – 2021<br />

(USD Billion)<br />

• 6.4.2. China<br />

sales@marketresearchstore.com


<strong>Hepatitis</strong> C <strong>Drug</strong> <strong>Market</strong><br />

<br />

• 6.4.2.1. China hepatitis C drug market revenue, by application, 2015 –<br />

2021 (USD Billion)<br />

• 6.4.3. Japan<br />

• 6.4.3.1. Japan hepatitis C drug market revenue, by application, 2015 –<br />

2021 (USD Billion)<br />

• 6.4.4. India<br />

• 6.4.4.1. India hepatitis C drug market revenue, by application, 2015 –<br />

2021 (USD Billion)<br />

o 6.5. Latin America<br />

• 6.5.1. Latin America hepatitis C drug market revenue, by application, 2015 – 2021<br />

(USD Billion)<br />

• 6.5.2. Brazil<br />

• 6.5.2.1. Brazil hepatitis C drug market revenue, by application, 2015 –<br />

2021 (USD Billion)<br />

o 6.6. Middle East & Africa<br />

• 6.6.1. Middle East & Africa hepatitis C drug market revenue, by application, 2015<br />

– 2021 (USD Billion)<br />

Chapter 7. Company Profiles<br />

o<br />

7.1. Merck & Co<br />

• 7.1.1. Overview<br />

• 7.1.2. Financials<br />

• 7.1.3. Product portfolio<br />

sales@marketresearchstore.com


<strong>Hepatitis</strong> C <strong>Drug</strong> <strong>Market</strong><br />

o<br />

o<br />

o<br />

o<br />

• 7.1.4. Business strategy<br />

• 7.1.5. Recent developments<br />

7.2. Kenilworth<br />

• 7.2.1. Overview<br />

• 7.2.2. Financials<br />

• 7.2.3. Product portfolio<br />

• 7.2.4. Business strategy<br />

• 7.2.5. Recent developments<br />

7.3. Roche<br />

• 7.3.1. Overview<br />

• 7.3.2. Financials<br />

• 7.3.3. Product portfolio<br />

• 7.3.4. Business strategy<br />

• 7.3.5. Recent developments<br />

7.4. Basel Glaxosmith<br />

• 7.4.1. Overview<br />

• 7.4.2. Financials<br />

• 7.4.3. Product portfolio<br />

• 7.4.4. Business strategy<br />

• 7.4.5. Recent developments<br />

7.5. Gilead Sciences<br />

• 7.5.1. Overview<br />

sales@marketresearchstore.com


<strong>Hepatitis</strong> C <strong>Drug</strong> <strong>Market</strong><br />

o<br />

o<br />

o<br />

• 7.5.2. Financials<br />

• 7.5.3. Product portfolio<br />

• 7.5.4. Business strategy<br />

• 7.5.5. Recent developments<br />

7.6. Abbvie<br />

• 7.6.1. Overview<br />

• 7.6.2. Financials<br />

• 7.6.3. Product portfolio<br />

• 7.6.4. Business strategy<br />

• 7.6.5. Recent developments<br />

7.7. Bristol- Myers Squibb.d<br />

• 7.7.1. Overview<br />

• 7.7.2. Financials<br />

• 7.7.3. Product portfolio<br />

• 7.7.4. Business strategy<br />

• 7.7.5. Recent developments<br />

7.8. Johnson & Johnson<br />

• 7.8.1. Overview<br />

• 7.8.2. Financials<br />

• 7.8.3. Product portfolio<br />

• 7.8.4. Business strategy<br />

• 7.8.5. Recent Developments<br />

sales@marketresearchstore.com


<strong>Hepatitis</strong> C <strong>Drug</strong> <strong>Market</strong><br />

<br />

Chapter 8. Patents<br />

o 8.1. U.S. (US Patents)<br />

o 8.2. Europe (EP documents)<br />

o 8.3. Japan (Abstracts of Japan)<br />

o 8.4. Global (WIPO (PCT))<br />

<strong>Hepatitis</strong> C <strong>Drug</strong> <strong>Market</strong>: Browse the full report<br />

at http://www.marketresearchstore.com/report/hepatitis-c-drug-market-z62423<br />

sales@marketresearchstore.com


<strong>Hepatitis</strong> C <strong>Drug</strong> <strong>Market</strong><br />

<strong>Market</strong> Research Store<br />

Address: Suite #8138, 3422 SW 15 Street, Deerfield Beach, Florida 33442, USA<br />

Tel: +1-386-310-3803<br />

Tel: +1-855-465-4651 (US/CAN TOLL FREE)<br />

Email: sales@marketresearchstore.com<br />

Web : http://www.marketresearchstore.com<br />

sales@marketresearchstore.com

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!